Merck & Co. Stock News

A Dutch court rules in favor of Halozyme Therapeutics, barring Merck from selling subcutaneous Keytruda in eight European markets.

Biopharma company Halozyme said on Wednesday that a Dutch patent court ruled in its favor ​against Merck , ordering the drugmaker to halt the ‌manufacture and sale of injectable Keytruda in eight European markets.

Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, Jefferies says.

Vaxcyte stock catapulted Monday after its experimental pneumococcal vaccine proved it's not inferior to marketed shots from Pfizer and Merck.

Moderna stock rallied by triple digits when positive news rolled in for its cancer vaccine. But is mRNA ready to return to the limelight?

Merck said on Wednesday its experimental ​drug met the main goal ‌of a mid-stage study in patients with moderate-to-severe hidradenitis suppurativa, ​a chronic skin disease ​that causes painful lumps, abscesses ⁠and scarring.

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from MK-7240-012, a Phase 2b multicenter, randomized, double-blind, placebo-controlled trial evaluating tulisokibart, an investigational humanized monoclonal antibody targeting tumor necrosis factor-like cytokine 1A (TL1A), in pa...

Summit Therapeutics stock catapulted Tuesday after AstraZeneca made a $2 billion investment in the smaller biotech.